Geron Corporation
Geron Corporation (GERN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GERN · as of Jun 9, 2026
Key Statistics
Explore Geron Corporation Data
gern stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 22 · Buy rate: 77.3%
The GERN analyst consensus is Buy, based on ratings from 22 Wall Street analysts over the past 3 months. The average 12-month price target is $5.89, representing +421.24% upside from the current price of $1.13.
Competitors & Peers
gern competitorsGERN
ARVN
AVBP
DAWN
LENZ
REPLStock Performance
Full HistoryAbout Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a…
what is geron corporation · gern stock overview · geron corporation company profile · who is geron corporation ceo · gern NASDAQ · geron corporation headquarters · geron corporation business segments
About Stock Overview & Key Data
Geron Corporation (GERN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 31, 1996. As of the latest trading session, GERN stock price is $1.13, with a market capitalization of $724.9M. The stock has returned -28.40% over the past 12 months and -12.12% year-to-date.
According to 22 Wall Street analysts, the consensus rating for Geron Corporation stock is Buy, with an average 12-month price target of $5.89. In fiscal year 2025, Geron Corporation reported revenue of $183.9M and net income of -$85.8M. For detailed data — including Geron Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Geron Corporation (GERN) stock price is $1.13. The stock is traded on NASDAQ under the ticker symbol GERN. The 52-week range is $1.04 – $2.01.